PDCD1 and cancer: Immunomodulatory mAbs, such as T-cell engaging antibodies and antibodies targeting programmed cell death protein 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 (CRLA-4), have gained great success in the treatment of cancer.